Study Shows Acriflavine May Treat Cutaneous Leishmaniasis by Reducing Inflammation Rather Than Killing Parasites
Researchers found that acriflavine, an antimicrobial compound, reduced skin lesions in mice infected with cutaneous leishmaniasis without decreasing parasite numbers. The drug works by dampening the immune system's inflammatory response rather than directly fighting the infection. This suggests a new therapeutic approach targeting the body's excessive immune reaction rather than parasite control alone.
A new study published on bioRxiv demonstrates that acriflavine treatment significantly reduced lesion size in mice with cutaneous leishmaniasis, a parasitic skin disease, despite having no effect on parasite burden. The research reveals that acriflavine works by reducing dendritic cell activation and decreasing the production of IFN-gamma, a key inflammatory molecule that contributes to tissue damage. The findings challenge the conventional approach of focusing solely on parasite elimination, instead highlighting how excessive protective immune responses can worsen disease outcomes. By targeting hypoxia-driven pathways in infected skin tissue, acriflavine appears to limit immunopathology—damage caused by the immune system itself. The researchers propose this represents a host-directed therapeutic strategy that could benefit patients with cutaneous leishmaniasis, particularly those for whom current treatments have proven ineffective.
What's missing
The article does not discuss the current standard treatments for cutaneous leishmaniasis, their failure rates, or the timeline for potential clinical trials of acriflavine. Additionally, it lacks information about whether acriflavine has been tested in human subjects or what safety profile it has in humans.
How coverage differed
The bioRxiv preprint presents findings from a controlled laboratory study with neutral scientific framing. As a preprint server, bioRxiv has not undergone peer review, so the findings represent preliminary research that may require validation before clinical application.
What different sources said
- bioRxivCenter
Acriflavine treatment attenuates inflammatory pathology in cutaneous leishmaniasis independently of parasite control
Related
Experimental compound T2 shows promise in limiting breast cancer progression in mouse model
Researchers found that thiosemicarbazone T2, an experimental compound, suppressed cancer progression in a mouse model of triple-negative breast cancer by blocking a key cellular signaling pathway. The study used an immunocompetent mouse model that mimics how human breast cancer progresses from non-invasive to invasive forms. The findings suggest T2 could warrant further investigation as a potential treatment for this aggressive form of breast cancer.
Scientists Develop Cost-Effective Method to Extract Protein from Dried Leafy Vegetables
Researchers have developed a simple, scalable process to extract RuBisCO, Earth's most abundant protein, from dried leafy biomass like spinach, kale, and rocket. The method achieves approximately 70-90% extraction efficiency without resource-intensive processing, addressing a gap since most existing extraction techniques were designed for fresh material. This advancement could enable sustainable plant protein production from agricultural waste, supporting circular economy approaches in food supply chains.
Researchers Observe Synchronized Quantum Interactions Between Excitons and Phonons in Perovskite Nanocrystals
An international research team directly observed coherent quantum interactions between excitons (light-induced electronic excitations) and phonons (crystal lattice vibrations) in perovskite nanocrystals. This advance in understanding quantum dynamics in semiconductor materials was published in Nature Communications. The findings could improve understanding of energy transfer processes in quantum materials with applications in optoelectronics and quantum computing.